News

Get the latest from Biologics

We invite you to learn more about our work. Check out our organization’s recent news, and browse our press releases to see what we’ve been doing. You can also check out upcoming events in which we’ll be participating or read more about our how we give back to our community.

KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, available for order at Biologics, Inc.

CARY, N.C. (March 17, 2017) —Biologics, Inc. a McKesson Specialty Health oncology pharmacy services company, has been selected by Novartis to be a specialty pharmacy provider for KISQALI® (ribociclib). Approved by the U.S. Food and Drug Administration (FDA) on March 13, 2017, KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as… Read More

XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics, Inc.

CARY, N.C. (March 1, 2017) —Biologics, Inc. has been selected by Lexicon Pharmaceuticals to be a specialty pharmacy provider in the limited distribution network for XERMELO (telotristat ethyl). Approved by the U.S. Food and Drug Administration (FDA) on February 28, 2017, XERMELO is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea… Read More

RUBRACA (rucaparib) Approved for the Treatment of Advanced Ovarian Cancer, Available Immediately at Biologics, Inc.

CARY, N.C. (December 19, 2016) —Biologics, Inc. has been selected by Clovis Oncology, Inc. to be a specialty pharmacy provider in the limited distribution network for RUBRACATM (rucaparib). Approved by the U.S. Food and Drug Administration (FDA) on December 19, 2016, RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated as monotherapy for the treatment… Read More

CABOMETYX (cabozantinib) Tablets Approved for Advanced Renal Cell Carcinoma, available at Biologics, Inc.

CARY, N.C. — October 3, 2016 —Biologics, Inc. has been selected by Exelixis, Inc. to be a specialty pharmacy provider in the limited distribution network for CABOMETYXTM (cabozantinib) tablets. Approved by the U.S. Food and Drug Administration (FDA) on April 25, 2016, CABOMETYX is indicated for the treatment of patients with advanced renal cell carcinoma… Read More

Biologics, Inc. Raises over $15,000 for Blood Cancer Research and Patient Services

The Company’s Annual Food Truck Rodeo Raises Funds for The Leukemia & Lymphoma Society May 16, 2016 – Cary, NC – Biologics, Inc. is excited to announce that its annual Food Truck Rodeo for The Leukemia & Lymphoma Society raised $15,657, making it the largest fundraising event in the company’s history. The event featured liv… Read More

Venclexta (venetoclax) Approved for Chronic Lymphocytic Leukemia, available at Biologics, Inc.

CARY, NC — April 18, 2016 —Biologics, Inc. is pleased to announce the company has been selected by AbbVie Inc. to be a specialty pharmacy provider for VenclextaTM (venetoclax). Approved by the U.S. Food and Drug Administration on April 11, 2016, Venclexta is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) wit… Read More

McKesson Completes the Acquisitions of Biologics and Vantage Oncology

SAN FRANCISCO, April 4, 2016 – McKesson Corporation (NYSE:MCK), a leading international healthcare services and information technology company, announced today that it has completed the previously announced acquisitions of Vantage Oncology, LLC, and Biologics, Inc., for a combined purchase price of approximately $1.2 billion. About McKesson Corporation McKesson Corporation, currently ranked 11th on the FORTUNE… Read More

Biologics, Inc. to be Exclusive Specialty Pharmacy Provider for Vistogard® (uridine triacetate)

CARY, NC — March 3, 2016 —Biologics, Inc. is pleased to announce the company has been selected by BTG International Inc. as the exclusive specialty pharmacy provider for Vistogard® (uridine triacetate). In addition to accessing the drug via specialty distribution, BTG International Inc. will offer physicians and healthcare practices the opportunity to order Vistogard® throug… Read More

McKesson Expands Oncology Expertise with the Acquisitions of Vantage Oncology and Biologics

February 25, 2016 McKesson to acquire Vantage Oncology and Biologics in two transactions totaling $1.2 billion. Vantage is a leading national provider of radiation oncology, medical oncology and other value-based integrated cancer care. Biologics is the largest independent oncology-focused specialty pharmacy in the United States.  These acquisitions enhance McKesson Specialty Health’s services to patients, providers, payers and… Read More

Biologics, Inc. enters into definitive agreement to be acquired by McKesson Specialty Health

CARY, N.C. – February 25, 2016 – Biologics, Inc. is pleased to announce that the company has entered into a definitive agreement to be acquired by McKesson Specialty Health, a business unit of the McKesson Corporation. Biologics, an oncology pharmacy services company based in the Research Triangle, offers specialty pharmacy and patient support services specifically in… Read More